SLGL - Israel's Sol-Gel signs Canadian licensing deal for Twyneo Eposolay
2023-06-06 12:42:07 ET
Israel's Sol-Gel ( NASDAQ: SLGL ) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Eposolay.
Sol-Gel said it will receive up to $11M in upfront and milestone payments for the rights, plus royalties on net sales ranging from the low double-digits to high teens. The deal is for 15 years and is renewable in five-year periods.
Acne drug Twyneo and rosacea treatment Epsolay were both recently launched in the US. Sol-Gel licensed exclusive commercialization rights to the products in the US to Galderma.
More on Sol-Gel:
Sol-Gel Technologies GAAP EPS of -$0.41
Sol-Gel to acquire rare disorder drug patidegib for $4.7M upfront; plans $22.8M offerings
For further details see:
Israel's Sol-Gel signs Canadian licensing deal for Twyneo, Eposolay